The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Temybric Ellipta

GlaxoSmithKline Trading Services LimitedEU/1/19/1378/001-003

Main Information

Trade NameTemybric Ellipta
Active SubstancesFluticasone furoate
Umeclidinium bromide
Vilanterol trifenatate
Dosage FormInhalation powder, pre-dispensed
Licence HolderGlaxoSmithKline Trading Services Limited
Licence NumberEU/1/19/1378/001-003

Group Information

ATC CodeR03AL08 vilanterol, umeclidinium bromide and fluticasone f?u?r?o?a?t?e


License statusAuthorised
Licence Issued12/06/2019
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back